Table 3.
Serum 8-isoprostane and 4-HNE levels stratified by clinical, surgical, and pathological variables.
| 8-Isoprostane (pg/mL) | 4-HNE (ng/mL) | |||||
|---|---|---|---|---|---|---|
| Preoperative | Post-Resection | POD 1 | Preoperative | Post-Resection | POD 1 | |
| Age > 60 years | ||||||
| No | 59.9 (19.4–105.7) | 68.7 (30.7–172.8) | 17.5 (11.0–31.6) | 45.5 (28.0–61.3) | 30.6 (17.1–46.1) | 30.3 (17.0–45.0) |
| Yes | 73.9 (45.4–146.6) | 82.7 (49.6–190.5) | 23.6 (12.3–39.0) | 31.0 (18.8–52.2) | 24.5 (13.7–41.4) | 29.9 (18.3–42.1) |
| p-value * | 0.212 | 0.497 | 0.388 | 0.069 | 0.582 | 0.890 |
| Steatosis/Fibrosis | ||||||
| No | 64.1 (33.9–147.6) | 84.8 (37.7–172.8) | 21.7 (11.0–35.1) | 39.4 (19.7–58.0) | 25.1 (12.8–41.2) | 28.4 (15.2–39.0) |
| Yes | 69.1 (22.6–117.7) | 69.7 (30.6–176.2) | 27.6 (15.3–38.0) | 42.5 (25.4–62.5) | 39.9 (20.1–54.8) | 42.2 (29.7–56.7) |
| p-value * | 0.680 | 0.704 | 0.799 | 0.441 | 0.039 | 0.008 |
| Cholangiocarcinoma | ||||||
| No | 54.3 (30.6–103.3) | 58.6 (31.4–163.2) | 14.7 (8.9–33.5) | 38.8 (21.7–55.3) | 23.8 (14.5–40.9) | 30.2 (16.5–44.6) |
| Yes | 166.6 (46.7–229.2) | 163.6 (80.7–233.0) | 31.7 (24.3–39.7) | 54.6 (19.8–64.6) | 41.3 (14.2–49.8) | 30.3 (20.8–31.0) |
| p-value * | 0.014 | 0.043 | 0.007 | 0.330 | 0.161 | 0.823 |
| Neoadjuvant CTX | ||||||
| No | 66.8 (34.4–140.5) | 84.8 (42.4–195.9) | 23.5 (12.1–38.8) | 42.5 (23.6–60.6) | 32.9 (18.0–46.1) | 30.4 (21.9–43.4) |
| Yes | 64.0 (19.4–140.0) | 38.25 (24.2–143.5) | 13.4 (9.2–27.1) | 23.8 (16.4–48.9) | 11.5 (6.2–25.7) | 18.5 (8.1–33.9) |
| p-value * | 0.718 | 0.127 | 0.140 | 0.108 | 0.024 | 0.065 |
| Pringle maneuver | ||||||
| No | 77.6 (48.1–157.0) | 50.6 (27.5–167.2) | 28.8 (20.2–39.4) | 42.9 (25.5–58.2) | 41.3 (20.6–51.1) | 30.3 (19.0–46.8) |
| Yes | 54.3 (31.3–117.9) | 84.5 (38.0–174.3) | 13.7 (8.4–35.5) | 38.8 (19.6–58.9) | 19.9 (13.5–38.4) | 29.1 (15.7–39.5) |
| p-value * | 0.230 | 0.592 | 0.015 | 0.501 | 0.031 | 0.532 |
| Intraop. Transfusion | ||||||
| No | 77.6 (33.7–143.2) | 84.5 (30.5–174.3) | 22.2 (11.5–36.2) | 41.2 (19.8–55.4) | 20.5 (14.2–42.3) | 29.5 (17.2–40.7) |
| Yes | 49.4 (34.8–122.7) | 80.7 (43.6–185.8) | 27.5 (10.2–37.1) | 39.1 (28.4–61.8) | 35.6 (16.5–45.5) | 30.5 (19.1–46.5) |
| p-value * | 0.552 | 0.891 | 0.992 | 0.565 | 0.396 | 0.704 |
| Major/Minor | ||||||
| Minor | 59.9 (37.3–128.8) | 66.6 (25.0–151.1) | 24.8 (11.9–39.5) | 33.7 (20.0–55.2) | 29.9 (18.3–50.4) | 24.8 (11.9–39.5) |
| Major | 69.2 (31.9–145.3) | 84.8 (38.2–205.7) | 22.5 (11.1–32.9) | 41.7 (22.4–61.2) | 30.3 (17.0–40.4) | 22.5 (11.1–32.9) |
| p-value * | 0.633 | 0.326 | 0.586 | 0.341 | 0.874 | 0.552 |
* Mann–Whitney U test; all values are given as medians with interquartile range. Abbreviations: POD = postoperative day; CCC = cholangiocellular carcinoma; CTX = chemotherapy; intraop. = intraoperative.